LOGIN  |  REGISTER

Enhabit Announces Participation in Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$7.71 0.00 0.00

DALLAS / Aug 21, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, today announced its participation in two upcoming investor conferences.

Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer and Chief Financial Officer Crissy Carlisle will participate in the following events:

  • Jefferies Healthcare Services “Back to School” Summit and Bus Tour
    • When: Aug. 28
    • Venue: 1 Hotel Nashville in Nashville, Tenn.
  • 2024 Wells Fargo Healthcare Conference
    • When: Investor meetings and a fireside chat on Sept. 5
    • Venue: Encore Boston Harbor in Boston, Mass.
    • The fireside chat will be webcast live at 11 a.m. EDT and available for replay at https://investors.ehab.com under the events and presentations link.

About Enhabit Home Health & Hospice

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page